nuBioAge, a longevity science and wellness network in West Palm Beach, Florida, US has teamed up with Marius Pharmaceuticals for a collaborative GLP-1 comparison study in male patients.
The partnership involves their new assessment and research centre, nuHx.
The study aims to assess the effects of GLP-1s on muscle mass in men using Kyzatrex (testosterone undecanoate) CIII capsules for weight loss.
Kyzatrex, developed by Marius Pharmaceuticals, is an US Food and Drug Administration (FDA)-approved oral testosterone treatment for men.
The study seeks to establish the cause-and-effect relationship between muscle mass loss and energy reduction caused by GLP-1s.
The goal is to develop a first-of-its-kind treatment that uses testosterone to mitigate these side effects and support muscle growth during weight loss therapy.
For the trial, Marius Pharmaceuticals will provide Kyzatrex. nuBioAge will manage the study design and data interpretation, while nuHx will conduct patient assessments.
Patients will be recruited and supplied with medication via Progress Pharmacy, with study design and data analytics support from Palm Beach Atlantic University’s School of Pharmacy.
This study will evaluate the effects of combining GLP-1 therapy with Kyzatrex on muscle mass and energy levels in male patients.
Key metrics, including muscle mass retention, testosterone levels, and VO2 max, will be assessed using advanced biomarker tools like PNOE, Dexascan, and other lab-based methods.
nuHx provides comprehensive health assessments to monitor these effects in men on GLP-1 therapy.
nuBioAge co-owner and Progress Pharmacy head pharmacist Franck Kacou said: “GLP-1s are one of the most revolutionary therapies we have to treat obesity and overall metabolic disorders.
“We can enhance the positive benefits of weight loss by improving Body Mass Index (BMI) and body composition in male patients to maintain muscle mass, strength, and energy levels through proper biomarker monitoring and TRT.
“As a result, we can directly impact and improve a patient’s health span, quality of life, and longevity plan.”
The study will begin in December this year at nuHx’ headquarters in West Palm Beach and conclude in May 2025.
nuBioAge and its partner network aim to conduct studies like this to enhance physician education and knowledge in longevity treatments.
